Physician profile
Faiz Javed
NPI 1396162228
$1,725.39
in general payments reported to CMS, 2019-2025
16 companies · $114 in 2025
The $114 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $207 · 2020: $236 · 2022: $569 · 2023: $499 · 2024: $100 · 2025: $114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $713.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $712.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $517.06 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $256.44 | 2019-2023 | Trulance |
| Evoke Pharma, INC. | $219.70 | 2022-2023 | Gimoti |
| Gilead Sciences, INC. | $141.20 | 2020-2022 | |
| Celgene Corporation | $120.41 | 2022-2023 | Zeposia |
| Redhill Biopharma INC. | $85.39 | 2022-2023 | Movantik, Talicia, Aemcolo |
| Galderma Laboratories, L.P. | $70.58 | 2025 | Dysport |
| Merck Sharp & Dohme LLC | $64.92 | 2022-2023 | Dificid |
| Janssen Biotech, INC. | $62.01 | 2022-2023 | Stelara, Remicade, Simponi |
| Janssen Scientific Affairs, LLC | $39.18 | 2019 | |
| Braintree Laboratories, INC. | $31.88 | 2022 | |
| Capsovision, INC. | $30.39 | 2024-2025 | Capsocam Plus |
| Intercept Pharmaceuticals, INC. | $27.70 | 2025 | |
| Mauna Kea Technologies, INC. | $23.26 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.27 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $15.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faiz Javed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.